CSIMarket


Cytokinetics Incorporated  (CYTK)
Other Ticker:  
 


 

Cytokinetics Incorporated

CYTK's Financial Statements and Analysis



Cytokinetics Incorporated narrowed third quarter of 2023 net loss per share of $-1.35 compare to net loss per share of $-1.52 recorded in the same quarter a year ago a decrease compare to $-1.34 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -1.35 $  0 Mill
$+0.17     $-2M     -84.97 %



Cytokinetics Incorporated's Revenue fell by -84.97 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by -56.4 % sequentially.


Cytokinetics Incorporated is

More on CYTK's Income Statement



Cytokinetics Incorporated in the third quarter of 2023 recorded net loss of $-129.422 million, an improvement compare to net loss of $-142.310 million in III. Quarter a year ago.

Sequentially net loss advanced

More on CYTK's Growth

Cytokinetics Incorporated Inventories
CYTK's Cash flow In the third quarter of 2023 company's net cash flow was $31 million, capital expenditures grew by -6.331-96.53%, to $0 millions compare to same quarter a year ago

More on CYTK's Cash flow Statement


Cytokinetics Incorporated does not pay out common stock dividend.

In trailing twelve-month period Cytokinetics Incorporated payed $ -4.57 cash per share, on a free-cash flow basis .


Tangible Book value fell to $ -4.58 per share from $ -3.47.

Company repurchased 0.13 million shares or 0.14 % in Sep 30 2023.


More on CYTK's Dividends

 Market Capitalization (Millions) 5,810
 Shares Outstanding (Millions) 96
 Total Debt (Millions $) 61
 Revenue (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -527
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) -5
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 202




Cytokinetics Incorporated does not pay out common stock dividend.

In trailing twelve-month period Cytokinetics Incorporated had negative $ -4.57 cash flow per share, on a free-cash flow basis .


Tangible Book value fell to $ -4.58 per share from $ -3.47.

Company repurchased 0.13 million shares or 0.14 % in Sep 30 2023.


More on CYTK's Balance Sheets

 Market Capitalization (Millions) 5,810
 Shares Outstanding (Millions) 96
 Total Debt (Millions $) 61
 Revenue (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -527
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) -5
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 202
   


  News about Cytokinetics Incorporated Earnings

Cytokinetics Incorporated shows promising signs of growth with reduced losses in fiscal year 2023

The stock market can be a roll...

Cytokinetics Incorporated Reports Significant Challenges in Q2 2023

As a stock market journalist, it is my duty to in...

Cytokinetics Incorporated's Revenue Surges, but Elusive Profitability Remains a Challenge

Cytokinetics Incorporated is a biopharmaceutical company that is dedicated to improving the lives of patients with serious medical conditions. The company has a number of products in clinical development which include drugs for the treatment of cardiac dysfunction in patients with heart failure and therapies for the treatment of neurological disorders.
Despite their mission to improve patient lives, the company has been struggling financially, as evidenced by their recent financial reports. Cytokinetics Incorporated recorded a cumulative net loss of $-431 million during 12 months ending in the first quarter of 2023, resulting in a negative Date modified: 2023-11-06T19:11:58+00:00



CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com